Clinical trials: Viral Load
Corona Virus Infection, Stroke
Physiotherapy as a Complimentary Treatment in Reducing Viral-Load, Complications, Death, Expedite Discharge and Improve Quality of Life, Exercise Endurance and Capacity in Stroke Survivors With CoViD-19: A Clinical-Controlled Study
Background: Coronavirus (CoViD-19) positive stroke survivors (SSv) with comorbidities faces possibility for mortality. Study reports success of physiotherapy in CoViD-19 positive SSv with multiple comorbidities.
- Trial name
- NCT04471831
- Testing
- Rehabilitation exercise protocol
- Volunteers
- 30 people
- Sponsor
- University of Lagos, Nigeria
Chronic Hepatitis B
PEG-IFN in HBV Patients With Incomplete Response to NA
Treatment with a nucleoside analogue and subsequent viral decline has shown to partially restore immune hyporesponsiveness in chronic hepatitis B patients.
- Trial name
- PADD (NCT00883844)
- Testing
- Nucleos(t)ide analogue treatment with a peginterferon add-on strategy, Nucleos(t)ide analogue treatment
- Where
- 2 sites in Netherlands
- Volunteers
- 11 people
- Sponsor
- Foundation for Liver Research
HIV Infections
Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir
Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavir/ritonavir or…
- Trial name
- NCT00120393
- Testing
- atazanavir/ritonavir +2 NRTIs (immediate Switch Group), LPV/r +2 NRTIs (Delayed/optional Switch Group)
- Where
- 14 sites in United States, Canada
- Volunteers
- 192 people
- Sponsor
- Bristol-Myers Squibb
HIV-2 Infection
RESIST-2: 2nd-line ART for HIV-2 Infection
Prospective, longitudinal, open label, HIV-2 viral load and antiretroviral resistance informed 2nd-line ARV implementation study.
- Trial name
- RESIST-2 (NCT03394196)
- Testing
- HIV-2 Genotypic Drug Resistance Testing using DBS, 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID), 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )
- Where
- 2 sites in Senegal
- Volunteers
- 152 people
- Sponsor
- University of Washington
HIV -1 Infection
Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life (2)
The goal of this clinical trial is to learn if subcutaneous ePGT121v1-LS and VRC07-523-LS added to standard antiretroviral therapy (ART) is safe and helps improve HIV viral suppression in infants living with HIV in Mozambique and…
- Trial name
- ENABLE 2 (NCT07655141)
- Testing
- Broadly neutralizing antibody (bNAb) ePGT121v1-LS, Saline (0.9% NaCl), Broadly neutralizing antibody (bNAb) VRC07-523-LS
- Volunteers
- 73 people
- Sponsor
- Hospital Universitario 12 de Octubre
Covid19
A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19
The purpose of this study is to determine both the magnitude and duration of viral load (copies/mL) reduction after a single dose of OPN-019.
- Trial name
- NCT05035576
- Testing
- OPN-019
- Where
- Mexico
- Volunteers
- 8 people
- Sponsor
- Optinose US Inc.
HIV Infections, AIDS-Related Opportunistic Infections
When to Start Anti-HIV Drugs in Patients With Opportunistic Infections
The purpose of this study is to evaluate the effect of starting anti-HIV drugs in HIV infected patients who are being treated for opportunistic infections (OIs).
- Trial name
- NCT00055120
- Testing
- Emtricitabine/tenofovir disoproxil fumarate, Lopinavir/ritonavir, Stavudine
- Where
- 45 sites in United States, Puerto Rico and 1 more
- Volunteers
- 283 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Pilot Study of LTB4 in HIV-1 Infected Adults
This is a pilot study to assess the safety and antiretroviral activity of a naturally occuring substance known as Leukotriene B4(LTB4).
- Trial name
- NCT00251537
- Testing
- LTB4
- Where
- 7 sites in Canada
- Volunteers
- 40 people
- Sponsor
- LTB4 Sweden AB
Acute Respiratory Tract Infections
Effects of Nasal-spraying LiveSpo Navax in Treatment of Influenza Virus in Children
Acute Respiratory Tract Infections (ARTIs) in children are common diseases, with influenza virus types A and B is one of the main causes of serious symptoms in young children.
- Trial name
- NCT05378022
- Testing
- LiveSpo Navax, 0.9% NaCl physiological saline
- Where
- Vietnam
- Volunteers
- 70 people
- Sponsor
- National Children's Hospital, Vietnam
HIV Infections
Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen
ACTG 388 was a clinical trial that compared three- and four-drug anti-HIV drug regimens and demonstrated the effectiveness of a three-drug regimen.
- Trial name
- NCT00014937
- Testing
- lopinavir/ritonavir, lamivudine/zidovudine, efavirenz
- Where
- 37 sites in United States, Italy and 1 more
- Volunteers
- 240 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)
The HIV integrase inhibitor, raltegravir (RAL), which was recently approved by the FDA, has been shown in several trials to be highly effective.
- Trial name
- NCT00660972
- Testing
- Raltegravir, Emtricitabine/tenofovir disoproxil fumarate
- Where
- 15 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)
To determine the relapse rate at 24 weeks follow up in Hepatitis C Virus Genotype 1 Low Viral Load (HCV LVL G1) patients treated for 24 weeks with Peg Intron and Rebetol who are Hepatitis C Virus-Ribonucleic Acid (HCV-RNA)…
- Trial name
- NCT00709228
- Testing
- PegIntron, Rebetol
- Volunteers
- 496 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Safety and Effectiveness of the Drug DPC 083 in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Patients Who Are Failing Treatment With Nonnucleoside Reverse Transcriptase Inhibitors
The purpose of this study is to determine the safety and tolerability of the study drug DPC 083 combined with 2 nucleoside reverse transcriptase inhibitors (NRTIs) in HIV-infected patients who are failing their nonnucleoside…
- Trial name
- NCT00007449
- Testing
- DPC 083
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dupont Applied Biosciences
HIV, AIDS
HIV Viral Load Monitoring in Resource-Poor Settings
No randomized clinical trial to date has demonstrated a survival benefit of using regular HIV-1 ribonucleic acid (RNA) viral load (VL) testing to monitor patients' responses to antiretroviral therapy (ART) for HIV infection.
- Conditions
- HIV, AIDS, HIV Infections
- Trial name
- NCT00929604
- Testing
- HIV-1 viral load testing
- Where
- Zambia
- Volunteers
- 2,112 people
- Sponsor
- University of Alabama at Birmingham
COVID-19 Respiratory Infection, SARS-CoV2 Infection
Echinaforce COVID-19 Shedding Study
Respiratory viruses pose a permanent threat to humans and society as demonstrated by the current Covid-19 pandemic. Novel drugs and vaccines provide a means for controlling illness.
- Trial name
- NCT04999098
- Testing
- Echinaforce Forte tablets, Echinaforce Chewable tablets, Echinaforce tincture
- Where
- Bulgaria
- Volunteers
- 40 people
- Sponsor
- A. Vogel AG
HIV Infections
Home-based AIDS Care Project
The Home-based AIDS care program pilot project delivers and monitors antiretroviral (ARV) and tuberculosis (TB) medications at the homes of 1,000 people with HIV living in a rural area of Uganda.
- Trial name
- NCT00119093
- Testing
- Laboratory and clinical monitoring regimens
- Where
- Uganda
- Volunteers
- 1,000 people
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections, Health Literacy
Trial Embedded in an Electronic Personal Medical Health Records
This is a research study to determine if a personal health record, called myHERO, will help improve health. A personal health record is a secure internet (also called online) tool that contains personal health information like…
- Trial name
- NCT00972348
- Testing
- Online access to a personal health record, No access to the PHR
- Where
- United States
- Volunteers
- 338 people
- Sponsor
- University of California, San Francisco
Chronic Hepatitis C, Hepatitis C (HCV)
Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults
To evaluate the effect of ribavirin on second phase plasma hepatitis C virus (HCV) ribonucleic acid (RNA) decline in participants who receive ombitasvir/ABT-450/ritonavir and dasabuvir with full dose ribavirin, low dose ribavirin…
- Conditions
- Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a
- Trial name
- NCT02493855
- Testing
- Ombitasvir/ABT-450/Ritonavir, Dasabuvir, Ribavirin (RBV)
- Volunteers
- 46 people
- Sponsor
- AbbVie
Hepatitis C
The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC
The purpose of this study is to determine if administering Mogroside Sweetener "PureLo" (the study substance) for 14 days will lower the hepatitis C viral load and liver function alanine aminotransferase (ALT) levels.
- Trial name
- PureLo (NCT00926120)
- Testing
- Mogroside sweetener (PureLo)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Brooke Army Medical Center
HIV/AIDS
Can Undetectable (Viral Load) = Untransmissible (Virus) Change the Life Course of Adolescents Living in Africa
The scientific breakthrough related to Undetectable (viral load) = Untransmissible (virus) has had a major impact on motivation to take up and adhere to antiretroviral therapy among people living with HIV all over the world.
- Trial name
- NCT05278559
- Where
- Zimbabwe
- Volunteers
- 300 people
- Sponsor
- Centre for Sexual Health and HIV/AIDS Research Zimbabwe